<DOC>
	<DOC>NCT02942017</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in up to 100 adult female subjects diagnosed with moderate postpartum depression</brief_summary>
	<brief_title>A Study to Evaluate SAGE-547 in Patients With Moderate Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression, Postpartum</mesh_term>
	<criteria>Key Subject either must have ceased lactating at Screening; or if still lactating or actively breastfeeding at Screening, must agree to temporarily cease giving breastmilk to their infant(s). Subject has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSMIV Axis I Disorders (SCIDI) Subject is â‰¤ six months postpartum Subject must be amenable to IV therapy Key Active psychosis Attempted suicide associated with index case of postpartum depression Medical history of bipolar disorder Note: suicidal ideation is not an exclusion. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>